KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inovio Pharmaceuticals (INO) Shares Outstanding (Weighted Average) (2016 - 2025)

Historic Shares Outstanding (Weighted Average) for Inovio Pharmaceuticals (INO) over the last 17 years, with Q3 2025 value amounting to $52.2 million.

  • Inovio Pharmaceuticals' Shares Outstanding (Weighted Average) rose 8538.65% to $52.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $52.2 million, marking a year-over-year increase of 8538.65%. This contributed to the annual value of $27.2 million for FY2024, which is 2249.16% up from last year.
  • Latest data reveals that Inovio Pharmaceuticals reported Shares Outstanding (Weighted Average) of $52.2 million as of Q3 2025, which was up 8538.65% from $38.8 million recorded in Q2 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Shares Outstanding (Weighted Average) peaked at $249.4 million during Q3 2022, and registered a low of $17.4 million during Q4 2021.
  • Moreover, its 5-year median value for Shares Outstanding (Weighted Average) was $28.1 million (2024), whereas its average is $88.8 million.
  • In the last 5 years, Inovio Pharmaceuticals' Shares Outstanding (Weighted Average) plummeted by 9102.26% in 2023 and then skyrocketed by 8538.65% in 2025.
  • Over the past 5 years, Inovio Pharmaceuticals' Shares Outstanding (Weighted Average) (Quarter) stood at $17.4 million in 2021, then grew by 14.27% to $19.9 million in 2022, then increased by 11.51% to $22.2 million in 2023, then rose by 22.49% to $27.2 million in 2024, then skyrocketed by 92.07% to $52.2 million in 2025.
  • Its last three reported values are $52.2 million in Q3 2025, $38.8 million for Q2 2025, and $38.6 million during Q1 2025.